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Eukaryotic elongation factor 2 kinase (eEF2K) negatively reg-
ulates the elongation stage of mRNA translation and is activated
under different stress conditions to slow down protein synthe-
sis. One effect of eEF2K is to alter the repertoire of expressed
proteins, perhaps to aid survival of stressed cells. Here, we
applied pulsed stable isotope labeling with amino acids in cell
culture (SILAC) to study changes in the synthesis of specific
proteins in human lung adenocarcinoma (A549) cells in which
eEF2K had been depleted by an inducible shRNA. We discov-
ered that levels of heat-shock protein 90 (HSP90) are increased
in eEF2K-depleted human cells as well as in eEF2K-knockout
(eEF2K/) mouse embryonic fibroblasts (MEFs). This rise in
HSP90 coincided with an increase in the fraction of HSP90
mRNAs associated with translationally active polysomes, irre-
spective of unchanged total HSP90 levels. These results indicate
that blocking eEF2K function can enhance expression of HSP90
chaperones. In eEF2K/ mouse embryonic fibroblasts (MEFs),
inhibition of HSP90 by its specific inhibitor AUY922 promoted
the accumulation of ubiquitinated proteins. Notably, HSP90
inhibition promoted apoptosis of eEF2K/ MEFs under pro-
teostatic stress induced by the proteasome inhibitor MG132.
Up-regulation of HSP90 likely protects cells from protein fold-
ing stress, arising, for example, from faster rates of polypeptide
synthesis due to the lack of eEF2K. Our findings indicate that
eEF2K and HSPs closely cooperate to maintain proper proteos-
tasis and suggest that concomitant inhibition of HSP90 and
eEF2K could be a strategy to decrease cancer cell survival.
Eukaryotic elongation factor 2 (eEF2)3 kinase (eEF2K) is an
atypical protein kinase that phosphorylates eEF2 on Thr-56 and
renders it unable to interact with ribosomes. By reducing the
availability of active eEF2, eEF2K slows down the elongation
stage of protein synthesis (1), which consumes the vast majority
of the energy used (99%) by protein synthesis. eEF2K is acti-
vated under diverse cell stresses such as hypoxia (2), low pH (3),
nutrient deprivation (4), and glycolytic stress (5), which are
hallmarks of tumor microenvironments, and where saving
energy or nutrients such as amino acids would benefit tumor
cell survival. eEF2K-knockout (eEF2K/) mice are healthy
and viable (2), showing that eEF2K is not required for normal
cell function under standard animal husbandry conditions. As
such, it has been suggested that eEF2K inhibitors could hold
therapeutic potential to treat some cancers while exerting min-
imal on-target side effects.
Notably, we recently reported that accelerated translation
rates lead to enhanced levels of translation errors and that
eEF2K serves to ensure accurate protein synthesis (6). In this
study, using pulsed stable isotope labeling with amino acids in
cell culture (pSILAC) combined with LC-MS/MS analysis, we
discovered that knocking down or deleting eEF2K in cells
increases the translational efficiencies of HSP90 mRNAs. This
may help cells to cope with higher levels of erroneously trans-
lated and thus misfolded proteins. Strikingly, inhibition of
HSP90 in eEF2K-null cells evoked apoptosis under conditions
of proteolytic stress, suggesting that concomitant inhibition of
HSP90 and eEF2K is detrimental to (cancer) cell survival.
Results
Knockdown or knockout of eEF2K increases HSP90 expression
To assess whether eEF2K affects the synthesis of specific pro-
teins under metabolic stress conditions, we applied pSILAC (7)
to label newly synthesized proteins metabolically and quantify
their rates of (differential) accumulation by LC-MS/MS. A549
cells expressing an isopropyl -D-1-thiogalactopyranoside
(IPTG)-inducible short hairpin RNA (shRNA) against EEF2K
were generated and treated with 2-deoxyglucose (2-DG), a non-
metabolizable glucose analog that induces metabolic stress by
inhibiting glycolysis, to activate eEF2K (5). They were subse-
quently incubated in culture medium containing heavy lysine
and arginine isotopologs for 2 h to label (“mass-tag”) newly
synthesized proteins (Fig. S1A). Proteins were extracted and
subjected to trypsin digestion after which the resulting peptides
were analyzed by LC-MS/MS (Fig. S1B).
This work was supported by Prof. Kris Gevaert, VIB Center for Medical Biotech-
nology. The authors declare that they have no conflicts of interest with the
contents of this article.
This article contains Figs. S1 and S2 and Table S1.
1 Both authors contributed equally to this work.
2 To whom correspondence should be addressed. E-mail: christopher.
proud@sahmri.com.
3 The abbreviations used are: eEF2, eukaryotic elongation factor 2; eEF2K,
eukaryotic elongation factor 2 kinase; pSILAC, pulsed stable isotope label-
ing with amino acids in cell culture; HSP90, heat-shock protein 90; MEF,
mouse embryonic fibroblast; IPTG, isopropyl -D-1-thiogalactopyranoside;
2-DG, 2-deoxyglucose; mTORC1, mTOR complex 1; WB, Western blot;
qPCR, real-time quantitative RT-PCR; Fluc, firefly luciferase; PI, propidium
iodide.
croACCELERATED COMMUNICATION
J. Biol. Chem. (2019) 294(18) 7169 –7176 7169








































































































































A total of 3,011 unique proteins were identified, of which the
SILAC ratios of 973 proteins could reliably be quantified (see
“Experimental procedures” and Table S1). We detected 78 pro-
tein groups that differed in their synthesis rates (p value 0.01)
upon knockdown of eEF2K (Fig. S1B). Furthermore, synthesis
of three members of the heat-shock protein molecular chaper-
one family (HSPA5, HSP90B1, and HSP90AA1) was up-regu-
lated upon eEF2K knockdown (Fig. S1B). Of note, HSP90 pro-
teins have been shown to interact with eEF2K, resulting in its
stabilization (8). SDS-PAGE followed by Western blot analysis
confirmed the higher HSP90 protein expression levels in
IPTG-treated A549 cells and eEF2K/ MEFs compared with
their vehicle-treated or WT counterparts, by 1.5- and 2.0-fold,
respectively. Also consistent with the pSILAC analysis,
GAPDH levels were 1.6- and 2.3-fold lower in IPTG-treated
A549 and eEF2K/ MEFs, respectively (Fig. S1, C–E). In con-
trast, actin levels were unaltered (Fig. 1A). 2-DG treatment also
led to a reduction in HSP90 protein levels in MEFs (Fig. 1, D
and E) (6). It was shown previously (9) that TOP mRNAs
(mRNAs that contain a 5-terminal oligopyrimidine tract,
many of which encode ribosomal proteins and translation
factors) are recruited onto polysomes upon activation of
eEF2K, thereby causing an increase in the relative synthesis
of TOP mRNA– encoded proteins compared with others.
This feature was clearly evident in our pSILAC data, in good
agreement with the findings of Gismondi et al. (9), thereby
validating our own findings.
eEF2K knockout shifts HSP90 mRNAs into polysomal fractions
Higher HSP90 protein levels in eEF2K-null cells were not due
to elevated levels of its mRNAs as, if anything, HSP90AA1 and
HSP90B1 mRNA levels were slightly lower in eEF2K/ MEFs
(Fig. 2, A and B). To study further how eEF2K regulates HSP90
protein expression, we fractionated lysates from 2-DG–treated
eEF2K/ and eEF2K/ MEFs through sucrose gradient pro-
filing (Fig. 2C). 2-DG treatment greatly reduced the proportion
of ribosomes in translationally active polysomal fractions (Fig.
S2). Interestingly, upon 2-DG–induced eEF2K activation (Fig.
1D), the amounts of HSP90AA1 and HSP90B1 mRNAs associ-
ated with active polysomes were higher in eEF2K/ MEFs
than in WT cells, and their association with monosomal or
subpolysomal fractions was correspondingly lower (Fig. 2,
C–E). In contrast, the distribution of a “control” mRNA, B2M
(encoding 2-microglobulin), was essentially unchanged (Fig.
2F). These data indicate that eEF2K negatively regulates the
translation of HSP90 mRNAs by impairing the association of
their mRNAs with polysomes.
Concomitant inhibition of HSP90 and eEF2K induces protein
ubiquitination and cell death
Higher levels of HSP90 may help cells to maintain adequate
protein folding under conditions of accelerated polypeptide
synthesis (translation elongation) caused by the absence of
eEF2K. Thus, blocking HSP90 function may be particularly det-
rimental to protein homeostasis (proteostasis) in cells lacking
eEF2K. To test this, we exposed eEF2K/ and eEF2K/
MEFs to MG132, a proteasome inhibitor, in the presence or
absence of the HSP90 inhibitor NVP-AUY922 (hereafter called
AUY922) (10). MG132 evokes phosphorylation of eEF2 (Fig.
3A), indicating activation of eEF2K. Under conditions of
impaired protein degradation, ubiquitinated proteins first
Figure 1. Knocking down or ablating eEF2K elevates HSP90 protein levels. A, lysates of A549 cells treated IPTG (to induce shRNA expression to knock
down eEF2K) or eEF2K/ and eEF2K/ MEFs were subjected to SDS-PAGE followed by WB analysis of the indicated proteins. B and C, quantification of HSP90
levels in A549 cells (B) or MEFs (C) from A. D, eEF2K/ and eEF2K/ MEFs were cultured in low-glucose (5.5 mM) DMEM  10 mM 2-DG for 24 h before
immunoblot analysis. E, quantification of HSP90 levels from D. P-eEF2, phosphorylated eEF2. *, 0.01  p  0.05; **, 0.001  p  0.01. Error bars represent S.D.
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accumulate in the fraction that is soluble in 1% (v/v) Triton and
then aggregate and relocate into the insoluble fraction (11).
As expected, after MG132 treatment, a large quantity of
ubiquitinated proteins was found in clarified lysates, and a
slight increase in ubiquitinated proteins in 1% (v/v) Triton
X-100 –insoluble pellets was also observed (Fig. 3, A–C). Inhib-
iting HSP90 activity by AUY922 increased levels of ubiquiti-
nated proteins in the pellet fraction in eEF2K/ MEFs, but the
effect was considerably enlarged in eEF2K/ cells (Fig. 3,
A–C), indicating a greater buildup of incorrectly folded pro-
teins. Furthermore, this was accompanied with poly(ADP-ri-
bose) polymerase cleavage (Fig. 3A), indicating apoptosis (12).
We observed a reduction in protein refolding capacity in
eEF2K/ MEF lysates from cells pretreated with MG132 and
AUY922 (Fig. 3D), showing that HSP90 inhibition greatly
impairs overall chaperone capacity in eEF2K-null cells. We also
detected a large increase in early and late apoptotic AUY922-
treated eEF2K/ cells under proteotoxic stress induced by
MG132 (Fig. 4), likely reflecting impaired proteostasis. Taken
together, these data indicate that when elongation rates are
enhanced, subsequent up-regulation of HSP90 chaperone
expression plays an important role in maintaining proteostasis.
Discussion
Proteostasis involves tightly-regulated and balanced pro-
cesses that are essential to cell and organ health span. The pro-
cesses that modulate proteostasis include the synthesis, matu-
ration, and degradation of proteins. It follows that mRNA
Figure 2. eEF2K knockout in MEFs shifts HSP90AA1 and HSP90B1 mRNAs from polysomal to non/subpolysomal fractions. A and B, eEF2K/ and
eEF2K/ MEFs were treated as in Fig. 1E, and total cell mRNA was extracted and subjected to qPCR with primers for HSP90AA1 (A) and HSP90B1 (B). C–F,
eEF2K/ and eEF2K/ MEFs were treated as in Fig. 1E, and cell lysates were subjected to polysome analysis. A representative profile is shown in C, and
positions of ribosomal/polysomal species are indicated. RT-qPCR was performed using specific primers for mouse HSP90AA1 (D), HSP90B1 (E), and B2M (F). *,
0.01  p  0.05; **, 0.001  p  0.01; ***, p  0.001. Error bars represent S.D.
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translation requires effective mechanisms to ensure the correct
folding and assembly of newly synthesized polypeptides into
functional proteins; dysregulation of this crucial process in cells
contributes to development of protein misfolding disorders
such as Alzheimer’s disease, Huntington’s disease, and amyo-
trophic lateral sclerosis (ALS) among others (13).
Conn and Qian (14) and we (6) recently reported that mTOR
complex 1 (mTORC1) (6, 14), ribosomal protein S6 kinases
(14), and eEF2K (6) function to optimize quality control during
protein synthesis. For example, faster translation elongation
resulting from eEF2K inhibition can lead to the production of
mistranslated proteins (6), and conversely, inhibition of
mTORC1 by rapamycin slows down translation elongation,
resulting in more accurate translation (14). Faster elongation
will increase the load of newly synthesized polypeptides that
need to be properly folded. Misfolded proteins are degraded,
but it is not clear how mTORC1 controls protein degradation
(15, 16); neither we (6) nor Conn and Qian (14) saw any detect-
able changes in chaperone capacity or proteasome activity
upon inhibition of mTORC1 or eEF2K. However, because
translation quantity is inversely related with quality, it is rea-
sonable to speculate that alterations in translation speed and
hence accuracy may also impact other proteostasis regulatory
mechanisms to ensure proper protein production.
Previously, we showed that levels of certain proteins involved
in cell migration are decreased upon eEF2K knockdown in
A549 cells (17). To measure the rates of de novo synthesis at the
proteome-wide level, we applied pSILAC (which enables the
identification and quantification of newly synthesized pro-
teins). Consistent with results from our study of steady-state
protein levels (17), we only observed changes in the synthesis of
a small proportion of proteins (78 of the 973 quantifiable pro-
teins) when comparing control and eEF2K knockdown cells
(Fig. S1). Among them, levels of HSP90 chaperones were
increased in A549 cells upon eEF2K knockdown and in
eEF2K/ MEFs (Fig. 1). This observation, however, was not
associated with increases in HSP90 mRNA levels but instead
resulted from increased translational efficiency of HSP-encod-
ing mRNAs (HSP90AA1 and HSP90B1) (Fig. 2) overall, ensur-
ing proper protein folding under accelerated rates of transla-
tion elongation. The mechanism by which depletion of eEF2K,
and thus faster elongation, increases translation of HSP90
mRNAs is not clear. One possibility is that their coding
sequences contain rare codons for which levels of the cognate
tRNAs are low; this appears not to be the case. Another is that it
relates to features of their 5-untranslated regions (UTRs),
regions that often control translation initiation. Notably, the
HSP90 5-UTR is known to possess extensive secondary struc-
ture (18) and may therefore make the translation of their
mRNAs more susceptible to modulation during elongation,
Figure 3. AUY922 increases levels of ubiquitinated proteins in 1% (v/v)
Triton–insoluble pellets from eEF2K/ MEFs. A–C, eEF2K/ and
eEF2K/ MEFs were cultured with vehicle or with 50 nM AUY922 and/or 3 M
MG132 for 24 h. Clarified cell lysates and detergent-insoluble pellets were
subjected to SDS-PAGE followed by WB analysis of the indicated proteins (A).
Levels of ubiquitin (Ub) in clarified lysates (B) and insoluble pellets (C) were
quantified. D, MEFs were treated as in A, and cell lysates were incubated with
previously heat-denatured Fluc at room temperature. Fluc refolding was
assessed by measuring Fluc activity at the indicated time points. P-eEF2, phos-
phorylated eEF2. *, 0.01  p  0.05; **, 0.001  p  0.01; ***, p  0.001. Error
bars represent S.D.
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although the mechanisms that link control of elongation to
modulation of initiation remain unclear (see Ref. 19).
Conversely, suppressing HSP90 activity using AUY922 led
to the accumulation of ubiquitinated proteins (Fig. 3) in
eEF2K/ cells and to apoptosis (Fig. 4), implying that eEF2K
and HSP90 jointly act to maintain proper proteostasis. It has
previously been reported that HSP90 physically interacts with
eEF2K, and disrupting the HSP90 – eEF2K interaction by
geldanamycin reduced eEF2K protein levels in glioblastoma
cells (8), suggestive of the requirement of HSP90 for the proper
folding and stability of eEF2K. Thus, eEF2K and chaperones
such as HSP90 form a mutually complementary system to
Figure 4. AUY922 induces apoptosis in eEF2K/ MEFs under proteolytic stress. eEF2K/ and eEF2K/ MEFs were treated as in Fig. 3A. A, cell viability
and morphology were assessed by microscopic analysis. Scale bars, 500 m. B, cells were dispersed, stained with annexin V (FITC-A) and PI (PI-A), and then
analyzed by flow cytometry. C, quantification of B. ***, p  0.001. Error bars represent S.D.
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ensure proper protein folding and protection of cells against
buildup of misfolded polypeptides. Furthermore, given the
growing interest in HSP90 and eEF2K inhibitors as anticancer
agents, a combination therapy involving both types of inhibi-
tors may offer a promising and effective strategy for therapy of
some types of cancer.
Experimental procedures
Chemicals and reagents
All reagents were from Sigma-Aldrich unless specified. Brad-
ford assay reagent was from Bio-Rad. IPTG was from Promega
(Alexandria, New South Wales, Australia). AUY922 was kindly
provided by Professor Lisa Butler (South Australian Health and
Medical Research Institute, Adelaide, South Australia, Austra-
lia) (20).
Cell culture, treatment, and lysis
A549 (human lung carcinoma) cells expressing inducible
shRNA against eEF2K were generously provided by Janssen
Pharmaceutica NV (Beerse, Belgium) (3). eEF2K-knockout
MEFs from eEF2K/ and eEF2K/ mice (2) were prepared
from embryos at embryonic day 13.5. The experimental proce-
dures were approved by the South Australian Health and Med-
ical Research Institute Animal Ethics Committee (ethics
approval number SAM220) and carried out in accordance with
the Australian code for the care and use of animals for scientific
purposes (2013). Cells were cultured in high-glucose (25 mM)
Dulbecco’s modified Eagle’s medium (DMEM; Life Technolo-
gies) supplemented with 10% (v/v) fetal bovine serum, 100
units/ml penicillin, and 0.1 mg/ml streptomycin and main-
tained at 37 °C in humidified air with 5% (v/v) CO2. For pSILAC
labeling, cells were cultured in low-glucose (5.5 mM) DMEM
(supplemented with dialyzed fetal bovine serum) containing
0.71 mM L-[13C6]Arg and 0.41 mM L-[13C6,15N2]Lys (Fig. S1A).
To induce eEF2K knockdown, 5 days before sampling 1 M
IPTG was added to A549 cells to induce expression of the
shRNA against eEF2K. Control cells were treated with the cor-
responding vehicle. Cells were collected by trypsinization,
washed twice with PBS (Thermo Fisher Scientific, Bremen,
Germany), and lysed in ice-cold lysis buffer (1% (v/v) Triton
X-100, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1
mM EGTA, 2.5 mM NaH2P2O7, 1 mM -glycerophosphate, 1
mM dithiothreitol (DTT), 1 mM Na3VO4, and protease inhibitor
mixture (1)). Lysates were centrifuged at 16,000  g at 4 °C for
10 min, and total protein concentrations in the supernatants
were quantified by Bradford assay. Where indicated, insoluble
pellets were dissolved in 1 Laemmli sample buffer (62.5 M
Tris-HCl (pH 6.8), 1% (w/v) SDS, 10% (v/v) glycerol, 10 M
DTT, and 5 g/ml bromphenol blue).
pSILAC labeling and LC-MS/MS analysis
As described in Fig. S1A, A549 cells were cultured in growth
medium with or without IPTG (to induce shRNA eEF2K
expression) for 5 days, medium was replaced by Arg/Lys-free
DMEM for 1 h, and cells were then incubated with 10 mM 2-DG
for 1 h before the addition of 0.71 mM L-[13C6]Arg and 0.41 mM
L-[13C6,15N2]Lys and further incubation for 2 h. Cell (5  106)
pellets were resuspended in PBS with equal volumes of 8 M
guanidine chloride HCl lysis buffer, lysed by three freeze–thaw
rounds in liquid N2, and processed for LC-MS/MS analysis as
described previously (21). All samples were introduced into an
LC-MS/MS system through an Ultimate 3000 RSLC nano LC
(Thermo Fisher Scientific) in line– connected to a Q Exactive
HF mass spectrometer (Thermo Fisher Scientific) (22).
Proteome data analysis
Raw data files were searched with MaxQuant (23) using the
Andromeda search engine (version 1.5.4.1) (24), and MS/MS
spectra were searched against the Swiss-Prot database (taxon-
omy, Homo sapiens; 20,198 entries; August 2016 version).
Potential contaminants present in the contaminants.fasta file
that comes with MaxQuant were automatically added. The pre-
cursor mass tolerance was set to 20 ppm for the first search
(used for nonlinear mass recalibration) and to 4.5 ppm for the
main search. Trypsin/P (i.e. cleavages between lysine/arginine-
proline residues were allowed) was selected as enzyme setting,
and up to two missed cleavages were allowed. Methionine oxi-
dation was searched as a fixed modification, whereas N-termi-
nal protein acetylation was set as a variable modification. The
false discovery rate for peptide and protein identification, esti-
mated by using the reversed search sequences, was set to 1%,
and the minimum peptide length was set to 7. The minimum
score threshold for both modified and unmodified peptides was
set to 40. The match between runs function with a match time
window of 0.7 min and an alignment time window of 20 min
was enabled, and proteins were quantified by the MaxLFQ algo-
rithm (25) integrated in the MaxQuant software. For SILAC
ratio quantification, the requantification feature was enabled,
multiplicity was set at 2, and the relative quantification of the
peptides against their SILAC-labeled counterparts (carrying
6Arg and/or 8Lys) was performed by MaxQuant. Only
unique peptides were used for quantification, and we required
proteins to be quantified with at least two ratio counts. For basic
data analysis, normalization, statistics, and annotation enrich-
ment analysis, the freely available open-source bioinformatics
platform Perseus (version 1.5.3.2) (26) was used. Data analysis
was done using the proteinGroups.txt file from MaxQuant.
Potential contaminants as well as reversed sequences and pro-
teins only identified by site (thus only by a peptide carrying a
modified residue) were removed from the data set. The repli-
cate samples were grouped, and the normalized heavy over light
protein ratios (i.e. in the case of normalized protein ratios, the
median of ratio subpopulations was shifted to 1) were log2-
transformed. A multiple-sample analysis of variance test was
applied with the S0 parameter set to 0.1 and a p value threshold
of 0.01 to assign proteins with significantly different pSILAC
protein ratios between groups, thereby reflecting differential
protein synthesis rates. Only proteins with minimally two valid
quantification values (i.e. SILAC ratios) in at least one group
were considered, and missing values were imputed from a nor-
mal distribution around the detection limit (with 0.3 spread and
1.8 downshift). Proteins with differential pSILAC ratios were
selected for subsequent Z-score normalization and k-means
clustering.
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SDS-PAGE and Western blot (WB) analysis
Western blot analysis were performed as described previ-
ously (7). Primary antibodies used were: HSP90 (Sigma-Al-
drich, catalog number 04-594), -actin (Sigma-Aldrich, catalog
number A5316), eEF2 (New England Biolabs, Hitchin, Herts,
UK, catalog number 2332), ubiquitin (New England Biolabs,
catalog number 3936), poly(ADP-ribose) polymerase (New
England Biolabs, catalog number 9542), and phosphorylated
eEF2 Thr-56 and eEF2K (custom-made by Eurogentec, Seraing,
Belgium). Fluorescently tagged secondary antibodies were from
Thermo Fisher Scientific. Blots were scanned using a LI-COR
Odyssey imaging system (Millenium Science, Mulgrave, Victo-
ria, Australia).
Real-time quantitative RT-PCR (qPCR) amplification analysis
Total RNA was extracted using TRIzol (Life Technologies).
cDNA was produced using the ImProm-II reverse transcription
system (Promega) with oligo(dT)15. For qPCR analysis of
sucrose gradient fractions, 1.2-kb kanamycin RNA provided by
the reverse transcription kit was used as an internal control.
qPCR was performed using the following primers (5–3):
mouse HSP90AA1: forward, CTGACGGACCCCAGTAA-
ACT; reverse, CCTGCAAAGCCTCCATGAAG; HSP90B1:
forward, AGTCGGGAAGCAACAGAGAA; reverse, TCTCC-
ATGTTGCCAGACCAT; B2M, forward, CTGCTACGTAAC-
ACAGTTCCACCC; reverse, CATGATGCTTGATCACATG-
TCTCG. Samples were analyzed with SYBR Green dye mix
(Life Technologies) on an ABI Step One Plus qPCR instrument
(Applied Biosystems, Cheshire, UK). For total RNA analysis,
B2M was used as the normalization control. The comparative
threshold cycle (CT) method was applied to quantify mRNAs
present in each sample.
Polysome analysis
Polysome analysis was performed as described previously (7).
For RNA extraction, 1% (w/v) SDS and 0.15 mg/ml proteinase K
were added to each fractions, 1:3 (v/v) phenol:chloroform, pH
4.5, was then added to the samples to extract RNA, and RNA
was precipitated from the aqueous phase by the addition of 70%
(v/v) isopropanol. RNA pellets were washed once with 80%
(v/v) ethanol before dissolving in RNase/DNase–free water for
further analysis.
In vitro refolding assay
Recombinant firefly luciferase (Fluc) (Promega) was diluted
in lysis buffer at 50 g/ml and then denatured at 42 °C at 1000
rpm for 15 min. Denatured Fluc was added to cell lysates for a
final concentration of 16.5 g/ml. Refolding was conducted at
room temperature at 1,000 rpm for the indicated periods of
time. Fluc activity was monitored with a luciferase reporter
assay system (Promega) on a Glomax Discover multimode
microplate reader (Promega) following the manufacturer’s
instructions. Fluc activity in lysis buffer alone was used as a
control to exclude spontaneous refolding of denatured Fluc.
Annexin V/propidium iodide (PI) staining
Following removal of culture media, the cells were washed
once with PBS and then incubated in 1 trypsin/EDTA (0.5%)
for 1 min at 37 °C. Growth medium was added, and the cells
were gently dispersed by pipetting and centrifuged at 200  g
for 5 min at room temperature. The medium was removed, and
annexin V/PI staining was performed using the Annexin-
V-FLUOS Staining kit (Sigma-Aldrich) according to the man-
ufacturer’s instructions. The intensity of fluorescence signals
was recorded using a FACSCantoTM II flow cytometer (BD Bio-
sciences), and data were analyzed using FlowJo software version
10.2 (BD Biosciences).
Statistical analysis
Statistical analyses were performed using one-way or two-
way analysis of variance with an unpaired Student’s t test with
the means of three independent experiments unless otherwise
specified. Data are presented as means  S.D. GraphPad Prism
software was used to calculate p values: *, 0.01  p  0.05; **,
0.001  p  0.01; ***, p  0.001.
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Supplementary Figure and Table Legends 
FIGURE S1. pSILAC analysis of de novo protein production in A549 cells. A, Schematic 
representation of pSILAC-labelling and 2-DG (10 mM) treatment before proteome extraction, proteome 
digestion and LC-MS/MS analysis. A549 cells were first cultured in growth medium with or without 
IPTG (to induce shRNA eEF2K expression) for 5 days, medium was replaced by Arg/Lys-free DMEM 
for 1 h, cells were then incubated with 10 mM 2-DG for 1 h, before the addition of  0.71 mM L-[13C]6-
Arg and 0.41 mM L-[13C]6, [15N]2-Lys and further incubation for 2 h. B, Cluster analysis after two-way 
ANOVA analysis. Significantly differing ‘genotype (-/+ IPTG)’ dependent pSILAC ratios are 
represented. Red indicates high H/L SILAC ratios while green indicates low H/L SILAC ratios. 
Treatment No. matches those in A. C, Lysates from Fig. 1A were subjected to SDS-PAGE/WB analysis 
for GAPDH. Quantified in D (A549) and E (MEFs). 
FIGURE S2. 2-DG reduces polysome levels in MEFs. WT MEFs were treated with or without 2-DG 
(10 mM) as in Fig. 1E, before subjected to polysome profiling analysis. Please note that the control 
(non-treated) gradient is identical to the eEF2K+/+ gradient in Fig. 2C. 
TABLE S1. Raw data for pSILAC and LC-MS/MS analysis. Related to Fig. S1. 
 


